SCHEMBL6490649

SCHEMBL6490649

CC(=O)Nc1ccc(-c2ccc(C(=O)NC3CC4CC3CN4)o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MMP13 P45452 1/20 0.48
MAPT P10636 3/20 0.43
RAB9A P51151 3/20 0.43
TP53 P04637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
PTPN1 P18031 3/20 0.42
PTPN11 Q06124 1/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPK1 P28482 1/20 0.41
HPGD P15428 1/20 0.40
MAPKAPK2 P49137 3/20 0.40
NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488949 0.89 NQO2 (0.51) KMT2AMMP13MAPTRAB9AALDH1A1
SCHEMBL6489595 0.87 MMP13 (0.43) MEN1KMT2AMMP13MAPTRAB9A
SCHEMBL6499550 0.87 MAPKAPK2 (0.41) MEN1KMT2AMAPTRAB9ATP53
SCHEMBL6485912 0.86 ALDH1A1 (0.43) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL6489856 0.86 ERCC5 (0.45) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL6499881 0.85 MAPKAPK2 (0.45) MEN1KMT2AMMP13MAPTRAB9A
SCHEMBL6486556 0.85 ALDH1A1 (0.42) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL6502351 0.85 ALDH1A1 (0.52) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL6489862 0.85 NPC1 (0.56) MAPTRAB9ATP53ALDH1A1KDM4E
SCHEMBL6495997 0.83 TUBB4A (0.45) MEN1KMT2AMAPTRAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 MEN1 1004/4885KMT2A 3836/4885MMP13 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.